TELA - TELA Bio wins FDA nod for soft tissue reconstruction product
2023-03-23 07:30:53 ET
- MedTech company TELA Bio ( NASDAQ: TELA ) announced Thursday that the FDA issued 510(k) clearance for its OviTex PRS Long-Term Resorbable product, a device used for soft tissue repair or reinforcement in plastic and reconstructive surgery.
- OviTex PRS Long-Term Resorbable is part of TELA Bio’s ( TELA ) OviTex PRS portfolio, which is made up of ovine rumen-derived tissue and reinforced with permanent or resorbable polymer for additional strength.
- In addition to OviTex PRS Long-Term Resorbable product, OviTex PRS portfolio includes OviTex PRS Permanent and OviTex PRS Short-Term Resorbable configurations.
- “This new offering expands the clinical utility of the OviTex PRS portfolio and demonstrates our ability to leverage the tunable design of OviTex PRS to meet the varying needs of surgeons and patients in plastic and reconstructive surgery,” TELA Chief Executive Antony Koblish remarked.
- Read: Seeking Alpha author Jonathan Faison termed TELA ( TELA ) as a long idea in biotech and healthcare for 2023.
For further details see:
TELA Bio wins FDA nod for soft tissue reconstruction product